Structure-Activity Relationship of the Agonist-Antagonist Transition on the Type 1 Angiotensin II Receptor; the Search for Inverse Agonists
Peptidic angiotensin II (Ang) antagonists have been mostly reported to behave in a more or less competitive fashion. Thus, reinforcing the view of competitive analogues being compounds which can reversibly bind without producing any biological response to the receptor as well as competing with an agonist (e.g. Ang or other peptidic agonists) for the same site. Recently, a new concept was introduced that changes the classical view of agonist-antagonist action. This concept presents the receptor as a dynamic structure capable of undergoing a conformational change between a biologically active and an inactive form. A bound ligand may shift the equilibrium to either side, according to its pharmacological character as an agonist or an antagonist: An antagonist favoring the inactive form of the receptor represents what is called an “inverse agonist”. All peptidic Ang analogues bind to the same locus on the AT1 receptor but non-peptidic AT1 binding compounds (e.g. L-158,809 and DuP 753) seem to bind to different loci. Furthermore, it has also been shown that non-peptidic Ang antagonists do not possess the ability to recognize Ang receptors from amphibian or avian origins. In the present contribution, we attempt to fathom the molecular parameters that bring the transition from an agonistic to an antagonistic behaviour in order to select the compounds that display most profoundly these antagonistic features. We believe to possess the necessary tools (enlarged but planar aromatic side-chains in position 8) in order to explore the concept of inverse agonism on the mammalian AT1 receptor.
KeywordsIntrinsic Activity Inverse Agonist Full Agonist Rabbit Aorta Recombinant Cell Line
Unable to display preview. Download preview PDF.
- 6.Costa, T., Ogino, Y., Munson, P.J., Onaran, H.O. and Rodbard, D., Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: Thermodynamic interpretation of negative antagonism and receptor activity in the absence of ligand, Mol. Pharmacol. 41 (1992) 549–560.PubMedGoogle Scholar
- 20.Servant, G., Escher, E. and Guillemette, G., Non-AT1 and non-AT2 binding sites observed in PC12 cells after confluency, (to be published).Google Scholar
- 24.Wong, P.C., Hart, S.D., Chiu, A.T., Herblin, W.F. Carini, D.J., Smith, R.D., Wexler, R.R. and Timmermans, P.B.M.W.M., Pharmacology of DuP 532, a Selective and Noncompetitive AT1 Receptor Antagonist, J. Pharmacol. Experm. Therap. 259 (1991) 861–870.Google Scholar
- 25.Chang, R.S.L., Siegl, P.K.S., Clineschmidt, B.V., Mantlo, N.B., Chakravarty, P.K., Greenlee, W.J., Patchett, A.A. and Lotti, V.J., In Vitro Pharmacology of L-158, 809, a New Highly Potent and Selective Angiotensin II Receptor Antagonist, J. Pharmacol. Experm. Therap. 262 (1992) 133–138.Google Scholar
- 27.Pérodin, J and Escher, E.(unpuplished results).Google Scholar
- 30.Leduc, R., Bernier, M. and Escher, E., Angiotensin-II Analogues. I: Synthesis and Incorporation of the Halogenated Amino Acids 3-(4′-Iodophenyl)alanine, 3-(3′, 5′-Dibromo-4′-chlorophenyl)alanine, 3-(3′, 4′, 5′-Tribromophenyl)alanine, and 3-(2′, 3′, 4′, 5′, 6′-Pentabromophenyl)alanine, Helvetica Chimica acta 66 (1983) 960–970.CrossRefGoogle Scholar
- 33.Tartar, A., Demarly, A., Sergheraert, C. and Escher, E., Metallocenic angiotensin II analogues, “Peptides ′83” V. Hruby (Ed) Pierce Corp., Rockford, III, 1984, pp. 377-380.Google Scholar
- 34.Hsieh, K.H., LaHann, T.R. and Speth, R.C., Topographic Probes of Angiotensin and Receptor: Potent Angiotensin II Agonist Containing Diphenylalanine and Long-Acting Antagonists Containing Bipheny-lalanine and 2-Indan Amino Acid in Position 8, J. Med. Chem. 32 (1989) 898–903.PubMedCrossRefGoogle Scholar